ANRS CO21 Cohort

{"level_sex_clusion_I":[{"value":"Male","concept":{"vocab":"MeSH","vocabURI":"D008297"}},{"value":"Female","concept":{"vocab":"MeSH","vocabURI":"D005260"}},{"value":"Other","concept":{"vocab":[],"vocabURI":[]}}],"level_age_clusion_I":[{"value":"Young Adult (19 to 24 years)","concept":{"vocab":"MeSH","vocabURI":"D055815"}},{"value":"Adult (25 to 44 years)","concept":{"vocab":"MeSH","vocabURI":"D000328"}},{"value":"Middle Aged (45 to 64 years)","concept":{"vocab":"MeSH","vocabURI":"D008875"}},{"value":"Aged (65 to 79 years)","concept":{"vocab":"MeSH","vocabURI":"D000368"}}],"level_type_clusion_I":"Patients population","level_type_clusion_other":"","clusion_I":"LTNP subjects: Long Term Non Progressors: HIV-1 positive subjects for at least 8 years with a CD4+ lymphocyte count greater than 600/mm3 and stable or increasing (positive or zero slope) on at least 3 consecutive tests performed in the last 5 years regardless of viral load in the absence of antiretroviral treatment. HIC (HIV Controllers)\" subjects: HIV-1 positive subjects for at least 5 years, asymptomatic, with the last 5 consecutive plasma HIV RNA viral loads < 400 copies/mL whatever the CD4+ level in the absence of antiretroviral treatment. LTNP-HIC\" subjects: subjects meeting the double definition of LTNP and HIC, i.e. HIV-1 subjects who have been HIV-positive for at least 8 years and CD4+ lymphocyte count greater than 600/mm3 with a stable or increasing level (positive or zero slope) on at least 3 consecutive examinations carried out over the last 5 years and with the last 5 consecutive plasma HIV-RNA viral loads < 400 copies/mL. Subjects in \"post-treatment control\" (or post-treatment controllers, PTC): Subjects who had a plasma HIV-RNA viral load > 2000 copies/mL prior to initiation of antiretroviral therapy in either primary or chronic phase and who were maintained on antiretroviral therapy for at least 12 months; in whom, after antiretroviral therapy was discontinued, the viral load remained < 400 copies/mL for more than 12 months with the exception of one blip (plasma viral load above 400 copies/mL) surrounded by two viral loads < 400 copies/mL. The last plasma viral load at the time of inclusion should, in all cases, be < 400 copies/mL.","clusion_E":""}